JAN (NYSE:JAN) to Issue Monthly Dividend of $0.05

JAN (NYSE:JAN) declared a monthly dividend on Friday, September 11th. Investors of record on Friday, October 16th will be given a dividend of $0.0475 per share on Wednesday, October 28th. This represents a $0.57 dividend on an annualized basis and a dividend yield of 2.0%. The ex-dividend date is Friday, October 16th.

JAN Price Performance

Shares of JAN stock opened at $28.87 on Wednesday. The business’s 50 day simple moving average is $30.12 and its 200 day simple moving average is $28.03. JAN has a 52-week low of $22.76 and a 52-week high of $32.83.

JAN (NYSE:JAN) last released its quarterly earnings results on Tuesday, August 4th. The company reported $0.05 earnings per share for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.18). The business had revenue of $216.46 million during the quarter, compared to analysts’ expectations of $203.32 million. JAN’s quarterly revenue was up 45.4% on a year-over-year basis. JAN has set its FY 2026 guidance at 0.950-0.980 EPS. As a group, equities analysts forecast that JAN will post 0.97 earnings per share for the current fiscal year.

Key JAN News

Here are the key news stories impacting JAN this week:

• Positive Sentiment: Barclays remains constructive on JAN with an overweight rating, and its revised target still implies approximately 14.3% upside from the referenced $28.87 price.
• Neutral Sentiment: The company’s latest quarter showed strong revenue growth of 45.4% year over year to $216.46 million, above expectations, while earnings per share of $0.05 missed the consensus estimate of $0.23. JAN maintained fiscal 2026 EPS guidance of $0.95 to $0.98.
• Negative Sentiment: The target-price cut from Barclays may reinforce concerns about valuation or execution, particularly as JAN shares remain below their 50-day moving average of $30.12.

JAN Company Profile

JanOne Inc (NYSE: JAN) is a publicly traded company focused on addressing the opioid crisis through the development and commercialization of solutions intended to improve the treatment and prevention of opioid use disorder. The company has described its mission as combining business, technology and scientific initiatives to help reduce opioid-related harm.

JanOne’s activities have included biotechnology and pharmaceutical-development initiatives, as well as investments in technologies and businesses connected with healthcare and financial services.